Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air
Co-medication
MASK-air
allergic rhinitis
visual analogue scale
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
23
02
2022
received:
04
01
2022
accepted:
28
02
2022
pubmed:
9
3
2022
medline:
9
9
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. We analysed 2015-2020 MASK-air We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
Sections du résumé
BACKGROUND
Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data.
METHODS
We analysed 2015-2020 MASK-air
RESULTS
We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H
CONCLUSIONS
Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
Substances chimiques
Histamine Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2699-2711Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
Bousquet J, Agache I, Anto JM, et al. Google trends terms reporting rhinitis and related topics differ in European countries. Allergy. 2017;72(8):1261-1266.
Bousquet J, Agache I, Berger U, et al. Differences in reporting the ragweed pollen season using google trends across 15 countries. Int Arch Allergy Immunol. 2018;176(3-4):181-188.
Bousquet J, Onorato GL, Oliver G, et al. Google trends and pollen concentrations in allergy and airway diseases in France. Allergy. 2019;74(10):1910-1919.
Bousquet J, Schroder-Bernhardi D, Bachert C, et al. Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clin Exp Allergy. 2021;51(8):1033-1045.
Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767.
Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: the MASK study. J Allergy Clin Immunol. 2019;144(1):135-143 e136.
Bedard A, Basagana X, Anto JM, et al. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clin Transl Allergy. 2020;10(1):62.
Bousquet J, Schunemann HJ, Togias A, et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80 e73.
Bousquet J, Anto JM, Bachert C, et al. ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice. Allergy. 2021;76(1):168-190.
Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019;9:16.
Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. Allergy. 2017;72(10):1475-1484.
Bousquet J, Arnavielhe S, Bedbrook A, et al. Treatment of allergic rhinitis using mobile technology with real world data: the MASK observational pilot study. Allergy. 2018;73(9):1763-1774.
Laune D, Arnavielhe S, Viart F, et al. Adaptation of the general data protection regulation (GDPR) to a smartphone app for rhinitis and asthma (MASK-air(R)). Rev Mal Respir. 2019;36(9):1019-1031.
Samreth D, Arnavielhe S, Ingenrieth F, et al. Geolocation with respect to personal privacy for the allergy diary app - a MASK study. World Allergy Organ J. 2018;11(1):15.
Kopp-Kubel S. International nonproprietary names (INN) for pharmaceutical substances. Bull World Health Organ. 1995;73(3):275-279.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Taylor and Francis Group; 1988.
Mavragani A, Ochoa G. Google trends in infodemiology and infoveillance: methodology framework. JMIR Public Health Surveill. 2019;5(2):e13439.
Dreher PC, Tong C, Ghiraldi E, Friedlander JI. Use of google trends to track online behavior and interest in kidney stone surgery. Urology. 2018;121:74-78.
Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. Allergy. 2018;73(9):1763-1774.
Brozek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958.
Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511 e441.
Bousquet J, Klimek L, Kuna P, Mullol J, Toppila-Salmi S. The debate: regular versus as-needed use of intranasal corticosteroids for a patient-centered approach. J Allergy Clin Immunol Pract. 2021;9(3):1374-1375.
Bousquet J, Bachert C, Canonica GW, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428-433.
Sousa-Pinto B, Eklund P, Pfaar O, et al. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®. Clin Transl Allergy. 2021;11(7):e12062.